Researchers discovered that the epidermal growth factor receptor (EGFR) plays an important role in the growth and spread of non-small-cell lung carcinoma.
Since this discovery, several studies have investigated how best to evaluate EGFR abnormalities.
Three landmark trials in 2004 showed that lung adenocarcinomas with mutated EGFR had significant responses to gefitinib and erlotinib. Dive deeper into the research.